JW Therapeutics

IPO

上海药明巨诺生物科技有限公司

Public · Shanghai, China · Founded 2016 · $190.0M raised

Headquarters
Shanghai
Employees
201–500
Founded
2016
Business Model
B2B
Total Funding
$190.0M
Last Round
$100.0M Series BJun 2020
Rounds
2
Type
Public

About

JW Therapeutics (HKEx: 2126) is an independent biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products in China and globally. Founded in 2016 and headquartered in Shanghai, the company's flagship product Carteyva® (relma-cel) is an approved anti-CD19 CAR-T therapy for relapsed/refractory large B-cell lymphoma. Its pipeline spans hematologic malignancies, solid tumors, and autoimmune diseases.

Summary

JW Therapeutics is a Biotech company based in Shanghai, China, founded in 2016. It has raised $190.0M in total across 2 rounds, most recently a $100.0M Series B round in Jun 2020. Investors include CPE Capital, Mirae Asset and ARCH Venture Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOSep 2020
$300.0M

Sign up to see all 3 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

JW Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/jw-therapeutics"><img src="https://indexed.vc/api/badge/company/jw-therapeutics" alt="JW Therapeutics on Indexed.vc" width="260" height="76" /></a>